We are currently updating our website. Please check back soon for our new look.

Go to the current website

Urodelia HAS DEVELOPED IN COLLABORATION WITH RESEARCHERS AND PRACTICING VETERINARIANS AN INNOVATIVE AND PATENTED IMMUNOTHERAPY METHOD TO TREAT CANCER IN PETS: APAVAC®

Apavac

For veterinarians

How does APAVAC KIT work ?

How does APAVAC® kit work?

The immune system of a dog with a cancer does not recognize the abnormal proteins produced by the tumor. Using the APAVAC® kit, the veterinary oncologist extracts the neoplastic lymph node and separates abnormal proteins. He injects them back into the ill dog’s body to make its immune system react against these proteins. Its T lymphocytes will then destroy the cancer cells.

Clinic results

Clinical results

APAVAC®’s immunotherapy solution improves the animal’s quality of life during its disease and extends significantly its overall survival compared to dogs undergoing chemotherapy treatment alone. APAVAC® is already used by European veterinary oncologists: APAVAC® is a reference at the Centro Oncologico Veterinario (COV), Italy. Scientific results were published in Clinical Cancer Research in February 2014.

Last publications

  • Clinical Cancer Research February 2014
    Randomized, Placebo-Controlled, Double-Blinded Chemoimmunotherapy Clinical Trial in a Pet Dog Model of Diffuse Large B-cell Lymphoma.
  • The Veterinary Journal March 2014
    Minimal residual disease detection by flow cytometry and PARR in lymph node, peripheral blood and bone marrow, following treatment of dogs with diffuse large B-cell lymphoma.

For pet owners

Can I use this treatment for my pet?

APAVAC®’s immunotherapy solution is a new kind of animal health -treatment. Our sole focus is on solving the medical needs of pets. We are working to bring scientific advances in immune oncology to pets and veterinary medicine.

News

Urodelia at ubistart 2014

Urodelia has been selected to attend the Ubistart Galien Tour in July 2014 to set up partnership leading to human healthcare applications worldwide. Human Clinical trials phase I-II are planned in Europe in 2014.

More information ?
Contact us at : info@apavac-vet.com